Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate Ointment for Vulvar HSIL
NCT06075264Phase 2Recruiting
- Sponsor
- Frantz Viral Therapeutics
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of artesunate in vulvar high-grade squamous intraepithelial lesion, sponsored by Frantz Viral Therapeutics. Started Dec 2023; status: recruiting.
02
Drugs
artesunate
03
Conditions
vulvar high-grade squamous intraepithelial lesion
Beyond the preview
Go deeper on NCT06075264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075264.